中医药干预对非小细胞肺癌患者生存期影响的回顾性分析

发布时间：2018-05-11 18:38

本文选题：非小细胞肺癌 + 中医药　；参考：《时珍国医国药》2017年07期

【摘要】：目的通过回顾性调查,分析中医药干预对246例非小细胞肺癌(NSCLC)患者生存期的影响。方法回顾性分析2010年至2014年上海市中医医院收治的246例非小细胞肺癌患者临床资料,采用Kaplan-Meirer法进行生存分析,Log rank检验和Cox模型预后影响因素行单因素和多因素分析。中医药干预分为中医组(中药静脉制剂、中药汤剂中的一种或两种),中西医结合组(化疗、放疗、靶向治疗中任意一项+中医药治疗),其中中药静脉针剂组按功效细分为(扶正药、祛邪药、扶正+祛邪药)。结果 246例患者1、3、5年生存率分别为72%、46%、26%,中位生存时间为37.4个月。中医组、中西医结合组中位生存期分别为29.14个月、45.73个月,1、3、5年生存率分别为61%、34%、25%;77%、52%、41%。单因素分析结果显示两组之间生存期的差异有统计学意义(χ~2=9.057,P=0.003)。中药静脉针剂+中药汤剂+化疗、中药静脉针剂+化疗、中药静脉针剂+中药汤剂、中药静脉针剂四组患者中位生存期分别为83.35个月、44.06个月、29.63个月、14.95个月,不同治疗方式对生存期的影响的差异具有统计学意义(χ~2=13.37,P=0.004)。中药静脉针剂中扶正组、祛邪药、扶正+祛邪药对生存期的影响无统计学差异(P0.05)。结论中西医结合治疗能延长非小细胞肺癌患者的中位生存期;同时采用中药静脉针剂+口服中药汤剂+化疗疗效最优;中药静脉针剂中扶正药、祛邪药、扶正联合祛邪药对生存期的影响无显著差异。
[Abstract]:Objective to analyze the effect of TCM intervention on the survival of 246 patients with NSCLC by retrospective investigation. Methods the clinical data of 246 patients with non-small cell lung cancer treated in Shanghai traditional Chinese Medicine Hospital from 2010 to 2014 were retrospectively analyzed. The survival analysis was performed by Kaplan-Meirer rank test and the prognostic factors of Cox model were analyzed by univariate and multivariate analysis. Chinese medicine intervention is divided into Chinese medicine group (traditional Chinese medicine intravenous preparation, traditional Chinese medicine decoction one or two kinds), integrated Chinese and western medicine group (chemotherapy, radiotherapy, Target treatment of any Chinese medicine treatment, its intravenous injection group according to the efficacy of subdivided into (tonifying drugs, dispelling evil drugs, Fuzheng dispelling evil drugs. " Results the 3- and 5-year survival rates of 246 patients were 722 / 46and 26.6, respectively. The median survival time was 37.4 months. The median survival time of TCM group and integrated traditional Chinese and western medicine group was 29.14 months, 45.73 months and 5-year survival rates, respectively. The results of univariate analysis showed that there was significant difference in survival time between the two groups (蠂 ~ (2) 9.057% P ~ (0.003). The median survival time of the four groups were 83.35 months, 44.06 months, 29.63 months and 14.95 months, respectively. The difference of survival time between different treatment methods was statistically significant (蠂 ~ (2 +) 13.37) P ~ (0.004). There was no significant difference in the effect of Fuzheng group, pathogenic drugs and Fuzheng pathogenic drugs on the survival time of Chinese traditional medicine intravenous injection (P 0.05). Conclusion the combination of traditional Chinese medicine and western medicine can prolong the median survival time of patients with non-small cell lung cancer, at the same time, the Chinese medicine intravenous injection with oral Chinese medicine decoction is the most effective. There was no significant difference in the effect of Fuzheng combined with pathogenic drugs on survival time.
【作者单位】：上海中医药大学附属市中医医院;北京市中医医院顺义医院;
【基金】：上海市卫生局科研课题项目(No.20134351) 上海市卫生和计划生育委员会中医药科研基金项目(No.2014LP075A)
【分类号】：R273

【参考文献】